Publikation

Hematocrit Self-Testing in Patients with Polycythemia Vera and Other Hematological Conditions: Assessing the Accuracy of the StatStrip Xpress 2 LAC/Hb/Hct Device and User Opinion about the Device in Real-World Clinical Practice.

Wissenschaftlicher Artikel/Review - 21.07.2022

Bereiche
PubMed
DOI
Kontakt

Zitation
Rovó A, Baierlein-Leimbach C, Medri C, Chanias I, Errass L, Fehr T, Triemer T, McCarthy-Pontier D, Lehmann T. Hematocrit Self-Testing in Patients with Polycythemia Vera and Other Hematological Conditions: Assessing the Accuracy of the StatStrip Xpress 2 LAC/Hb/Hct Device and User Opinion about the Device in Real-World Clinical Practice. J Clin Med 2022; 11
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
J Clin Med 2022; 11
Veröffentlichungsdatum
21.07.2022
ISSN (Druck)
2077-0383
Kurzbeschreibung/Zielsetzung

Maintaining hematocrit (Hct) levels below 45% can reduce morbidity and mortality in patients with polycythemia vera (PV). A device that patients can use to self-monitor Hct levels could enable timely interventions if Hct levels increase above 45%, and could improve quality of life (QoL). This study evaluated the accuracy of the StatStrip Xpress 2 LAC/Hb/Hct meter (Hb/Hct meter) when used by healthcare professionals (HCPs) or patients in clinical practice. Blood samples from 68 visits for 60 patients with PV or other hematological conditions were collected and analyzed by HCPs using a laboratory hematological analyzer, and by patients (self-test) and HCPs (professional test) using the Hb/Hct meter at two Swiss centers. Accuracy was assessed as the mean difference in readings between two users/methods (, 90% confidence interval; Spearman correlation []). The Hct values were similar between the professional test and analyzer ( = 66 comparisons, = 0.1% [-0.5 to 0.8]; = 0.95, < 0.001), the self-test and professional test ( = 62 comparisons, = -0.2% [-1.1 to 0.7]; = 0.93, < 0.001), and the self-test and analyzer ( = 63 comparisons, = 0.0% [-0.8 to 0.7]; = 0.94, < 0.001). The hemoglobin values across users/methods were also similar. Reporting their opinion on the Hb/Hct meter at visit 1, 100% of the patients found it easy to use, and 97% were willing to use it at home. Of the patients with PV, approximately 71% and 56%, respectively, stated that they would feel safer using a self-testing device, and that it would improve their QoL. These findings demonstrate the potential of the Hb/Hct meter for HCP and patient use in real-world settings.